Cargando…

A study of clinical and molecular characteristics in bilateral primary breast cancer

BACKGROUND: Bilateral primary breast cancer (BPBC) is a rare type of breast cancer. Studies on the clinicopathologic and molecular characteristics of BPBC in a metastatic context are very limited. METHODS: A total of 574 unselected metastatic breast cancer patients with clinical information were enr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Bin, Xu, Weiqi, Cao, Jianing, Guo, Duancheng, Tao, Zhonghua, Jin, Juan, Hu, Xichun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469734/ https://www.ncbi.nlm.nih.gov/pubmed/37293877 http://dx.doi.org/10.1002/cam4.6226

Ejemplares similares

Chromatin Remodelling Molecule ARID1A Determines Metastatic Heterogeneity in Triple-Negative Breast Cancer by Competitively Binding to YAP
por: Wang, Ye, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials
por: Li, Bin, et al.
Publicado: (2023)

Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer
por: Jin, Juan, et al.
Publicado: (2023)

Clinicopathological characteristics and survival outcomes in breast carcinosarcoma: A SEER population-based study
por: Lin, Shuchen, et al.
Publicado: (2019)

Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
por: Cao, Jun, et al.
Publicado: (2022)

The molecular and clinicopathologic characteristics of bilateral breast cancer
por: Chen, S. F., et al.
Publicado: (2013)

An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer
por: Jia, Zhenya, et al.
Publicado: (2018)

Malic Enzyme 1 Indicates Worse Prognosis in Breast Cancer and Promotes Metastasis by Manipulating Reactive Oxygen Species
por: Liu, Chang, et al.
Publicado: (2020)

Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer
por: Wang, Jinyan, et al.
Publicado: (2022)

Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma
por: Wang, Jinyan, et al.
Publicado: (2023)

Clinicopathological, molecular and prognostic characteristics of cancer of unknown primary in China: An analysis of 1420 cases
por: Qi, Peng, et al.
Publicado: (2022)

Internal mammary lymph node recurrence: rare but characteristic metastasis site in breast cancer
por: Chen, Lei, et al.
Publicado: (2010)

Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
por: Liu, Chang, et al.
Publicado: (2020)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis
por: Xie, Yizhao, et al.
Publicado: (2022)

A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer
por: Zhao, Yannan, et al.
Publicado: (2017)

Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers
por: Tao, Zhonghua, et al.
Publicado: (2021)

Bilateral Primary Angiosarcoma of the Breast
por: Keshav, P., et al.
Publicado: (2013)

PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR
por: Jin, Jia, et al.
Publicado: (2020)

Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial
por: Wang, Leiping, et al.
Publicado: (2021)

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid
por: Zhao, Xinmin, et al.
Publicado: (2011)

Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study
por: Zhang, Jian, et al.
Publicado: (2022)

Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial
por: Zhao, Yannan, et al.
Publicado: (2018)

miR-331-3p Suppresses Cell Proliferation in TNBC Cells by Downregulating NRP2
por: Zhao, Mingchuan, et al.
Publicado: (2020)

Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer
por: Li, Ting, et al.
Publicado: (2021)

GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data
por: Gong, Chengcheng, et al.
Publicado: (2022)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Xie, Yizhao, et al.
Publicado: (2021)

Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
por: Lin, Ying, et al.
Publicado: (2020)

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer
por: Zhao, Yannan, et al.
Publicado: (2020)

Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma
por: Chen, Guang-Liang, et al.
Publicado: (2022)

Primary Angiosarcoma of the Breast after Bilateral Breast Reduction
por: Philip, Justus, et al.
Publicado: (2018)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2021)

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of (18)F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Gong, Chengcheng, et al.
Publicado: (2022)

An Analysis of Clinical Characteristics of Rare Bilateral Cerebral Peduncular Infarction
por: Chen, Hao, et al.
Publicado: (2019)

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
por: Hu, Xichun, et al.
Publicado: (2014)

Clinical characteristics and outcome of primary brain abscess: a retrospective analysis
por: Huang, Junying, et al.
Publicado: (2021)

Comparison of primary endpoints between publications, registries, and protocols of phase III cancer clinical trials
por: Liang, Fei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c5kooab4fojqk3s3mc20kqrmfa